Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ML, PWOD, NURO, CARA on Behalf of Shareholders
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, NURO, PWOD, CARA on Behalf of Shareholders
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - PWOD, CARA, NURO, VOXX

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.